Plus   Neg

Stock Alert: Akers Biosciences Soars 40% On Merger Deal With MyMD Pharma

Shares of Akers Biosciences Inc. (AKER) are currently spiking over 40% after announcing a merger deal with MyMD Pharmaceuticals, Inc.

AKER is trading at $2.43, up $0.71 or 41.28%, on the Nasdaq.

Akers' shareholders will own around 20% of the combined company, while MyMD's shareholders will own around 80%. The merger is expected to close in the first half of 2021.

Following the deal, the two companies will develop and sell MyMD's novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases.

MyMD intends to also continue to develop its second asset, SUPERA-1R, a drug platform based on a patent-protected, synthetic derivative of cannabidiol that seeks to target key cannabinoid receptor.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill, Inc. is teaming with e.l.f. Cosmetics to launch a limited edition beauty collection on March 10, aiming to support plant-based lifestyles and responsibly-sourced products. The e.l.f. x Chipotle makeup collection will comprise cruelty-free and vegan products inspired by Chipotle's responsibly-raised food. The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates.
Follow RTT